Advanced search
Publication Cover
Substance Abuse Volume 35, 2014 - Issue 2
Journal homepage
302
Views
11
CrossRef citations to date
0
Altmetric
CASE STUDY

Two Cases of Intranasal Naloxone Self-Administration in Opioid Overdose

Traci C. GreenDepartment of General Emergency Medicine, Rhode Island Hospital, Providence, Rhode Island, USA;The Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA;The Center for Prisoner Health and Human Rights, Providence, Rhode Island, USACorrespondence[email protected]
, PhD MSc,
Madeline RayDepartment of General Emergency Medicine, Rhode Island Hospital, Providence, Rhode Island, USA
, BA,
Sarah E. BowmanDepartment of General Emergency Medicine, Rhode Island Hospital, Providence, Rhode Island, USA
, MPH,
Michelle McKenzieThe Miriam Hospital, Providence, Rhode Island, USA;The Center for Prisoner Health and Human Rights, Providence, Rhode Island, USA
&
Josiah D. RichThe Miriam Hospital, Providence, Rhode Island, USA;The Center for Prisoner Health and Human Rights, Providence, Rhode Island, USA
, MD MPH
Pages 129-132 | Published online: 12 May 2014

REFERENCES

  • Binswanger IA, Stern MF, Deyo RA, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356:157–165.
  • Rosen DL, Schoenbach VJ, Wohl DA. All-cause and cause-specific mortality among men released from state prison, 1980–2005. Am J Public Health. 2008;98:2278–2284.
  • Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction. 2008;103:251–255.
  • Dietze P, Jolley D, Fry C, Bammer G. Transient changes in behaviour lead to heroin overdose: results from a case-crossover study of non-fatal overdose. Addiction. 2005;100:636–642.
  • Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309:657–659.
  • Green TC, McGowan SK, Yokell MA, Pouget ER, Rich JD. HIV infection and risk of overdose: a systematic review and meta-analysis. Aids. 2012;26:403–417.
  • Beletsky L, Rich JD, Walley AY. Prevention of fatal opioid overdose. JAMA. 2012;308:1863–1864.
  • Wheeler E, Davidson P, Jones T, Irwin K. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. MMWR Morb Mort Wkly Rep. 2012;61:101–105.
  • Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
  • Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158:1–9.
  • Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am J Public Health. 2009;99:402–407.
  • Davis C. Legal interventions to reduce overdose mortality: naloxone access and overdose good samaritan laws. 2012. Available at: http://www.networkforphl.org./ Accessed November 20, 2012.
  • Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction. 2008;103:979–989.
  • Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health. 2003;80:189–200.
  • Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson M. Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. J Urban Health. 2007;84:283–291.
  • Powis B, Strang J, Griffiths P, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction. 1999;94:471–478.
  • Latkin CA, Hua W, Tobin K. Social network correlates of self-reported non-fatal overdose. Drug Alcohol Depend. 2004;73:61–67.
  • Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106:1460–1473.
  • Hussain A, Kimura R, Huang CH. Nasal absorption of naloxone and buprenorphine in rats. Int J Pharm 1984;21:233–237.
  • Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 2007;90:261–269.
  • Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70(2 Suppl):S13–S27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.